Adagene Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Adagene Inc. is a clinical-stage biopharmaceutical company that develops antibody-based cancer therapies using its proprietary computational discovery platforms, including its masked antibody technology designed to improve safety and tumor targeting. Its pipeline includes antibody candidates in early- and mid-stage clinical trials for various solid tumors, often developed through partnerships with other pharmaceutical companies.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Tam Man KinChief Financial Officer | Buy | $6K | 2,000at $3.00 | Sep 23, 2026 |
| DO CUONG VDirector | Buy | $8K | 2,000at $3.75 | Aug 14, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable ADAG activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.